Ignore Biogen: Here Are 3 Better Stocks
Investors have been flocking to Biogen since the U.S. Food and Drug Administration approved its Alzheimer's treatment, Aduhelm, earlier this month. The stock has climbed 30% in about two weeks. But I'm concerned about how far the stock can go from here. Aduhelm has drawn criticism from experts regarding its efficacy and pricing. And Biogen's older blockbusters face generic competition.
So, I would hold off on buying Biogen at the moment. Instead, I would turn to the following three stocks. One has been posting double- and triple-digit revenue growth. The other is a pharmaceutical giant with a long history of dividend payments. And the third is a trillion-dollar leader in e-commerce and cloud computing. Let's take a closer look.
Image source: Getty Images.
Source Fool.com
